Eli Lilly (LLY) is one of the stocks most watched ... as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long-term stocks. Ken Fisher is a prominent American billionaire investment analyst ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the ...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...

We'll use ROE to examine Eli Lilly and Company (NYSE:LLY), by way of a worked example. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors ...

JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly reported this morning. I want to talk about their revenue growth number, and I'm going to put it in some context of some younger growth stocks. These are the yearly revenue growth ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...